Intellia Therapeutics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell NTLA and other ETFs, options, and stocks.

About NTLA

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases.

CEO

John M. Leonard

CEOJohn M. Leonard

Employees

526

Employees526

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2014

Founded2014

Employees

526

Employees526

NTLA Key Statistics

Market cap

2.00B

Market cap2.00B

Price-Earnings ratio

-3.83

Price-Earnings ratio-3.83

Dividend yield

—

Dividend yield—

Average volume

1.17M

Average volume1.17M

High today

$20.99

High today$20.99

Low today

$19.37

Low today$19.37

Open price

$20.11

Open price$20.11

Volume

1.03M

Volume1.03M

52 Week high

$47.48

52 Week high$47.48

52 Week low

$19.37

52 Week low$19.37

NTLA News

Simply Wall St 6h

Intellia Therapeutics, Inc.'s latest 3.8% decline adds to one-year losses, institutional investors may consider drastic measures - Simply Wall St

Key Insights Significantly high institutional ownership implies Intellia Therapeutics' stock price is sensitive to their trading actions The top 11 shareholde...

Yahoo Finance 3d

Intellia to Report Q1 Earnings: What's in the Cards? - Yahoo Finance

We expect investors to focus on Intellia Therapeutics, Inc.’s NTLA progress with the development of its portfolio of CRISPR-based gene-edited therapies when it...

Yahoo Finance 3d

Earnings Preview: Intellia Therapeutics, Inc. Q1 Earnings Expected to Decline - Yahoo Finance

Intellia Therapeutics, Inc. (NTLA) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended...

Analyst ratings

79%

of 28 ratings

Buy

78.6%

Hold

21.4%

Sell